Medicine News and Research

RSS

Millions of Americans suffer unnecessarily with itchy, gritty, watery eyes, say allergists

Millions of Americans suffer unnecessarily with itchy, gritty, watery eyes, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology in Phoenix, Nov. 11-16. The underdiagnosis, undertreatment and self-treatment of eye allergies may seriously diminish quality of life, allergists say.

16 Nov 2010

Food, drugs of abuse engage same brain systems, show studies

New animal research helps explain why some eat without hunger or to excess. The studies explore the biological effects of poor eating habits, showing that high-fat diets cause lasting brain changes that may impair healthy eating. Additional studies show that food and drugs of abuse engage many of the same brain systems. The findings were presented at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

16 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

Elsevier announces availability of eBook collections for advance purchase

Elsevier, the leading publisher of scientific, technical and medical information products and services, announced today its 2011 eBook collections available for advance purchase and to be released on SciVerse ScienceDirect, its online scientific knowledge platform.

16 Nov 2010

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

Diffusion Pharmaceuticals LLC today announced positive results of its Phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to peripheral artery disease (PAD).

16 Nov 2010

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Beth Israel Deaconess Medical Center (BIDMC) will join the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet), a clinical research network sponsored by the National Heart Lung and Blood Institute (NHLBI) to conduct randomized clinical trials to evaluate new and existing medications for the treatment of idiopathic pulmonary fibrosis (IPF). The network is made up of healthcare institutions from around the United States.

16 Nov 2010

cTnT blood biomarker may predict risk of cardiovascular problems: Study

Certain measures of the blood biomarker cardiac troponin T (cTnT), a cardiac-specific protein, using a highly sensitive test, are associated with the development of heart failure or cardiovascular death in older adults, according to a study that will appear in the December 8 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

16 Nov 2010

NPR reports on dengue vaccine progress

NPR's Shots blog examines progress in the search for a vaccine to protect against the dengue virus. WHO estimates that 2.5 billion people worldwide are at risk of getting dengue, and most of them are in Asia and Latin America, the blog writes.

16 Nov 2010

Researchers find additional work of oxytocin hormone

New human research suggests the chemical oxytocin dubbed the "cuddle hormone" because of its importance in bonding between romantic partners and mothers and children also influences feelings of well-being and sensitivity to advertising.

15 Nov 2010

New investigational drug is well tolerated in children with nmCF

PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine.

15 Nov 2010

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

15 Nov 2010

National health disparities conference wraps up with creative approaches, expectations for new healthcare reform

Focusing on the disparities in the quality of health care across demographic groups, the Fourth Annual National Conference on Health Disparities brought together White House officials and national and local healthcare executives to address a series of key questions about non-medical determinants of health quality and to recommend strategies to bring more equitable healthcare access to the underserved. The determinants discussed at the four-day-long conference, which began November 10, 2010 and concluded Saturday, November 13, 2010, included education levels, health literacy, poverty, public safety, community design, access to care, environmental quality and personal, government and corporate responsibility.

15 Nov 2010

Novel heart attack treatment results presented at premier USA cardiology forum

Regenerative medicine company Mesoblast Limited (ASX:MSB; USADR:MBLTY) has announced that positive preclinical trial results were presented at the American Heart Association’s annual conference in Chicago showing that the company’s proprietary “off-the-shelf” stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.

15 Nov 2010

Erroneous defibrillators: FDA new initiative to check safety

More problems are being reported in external defibrillators, the life-saving medical devices located in emergency rooms, airports and other public places. These Automated external defibrillators, or AEDs are generally used in patients who have suffered sudden cardiac arrest if used in the first few minutes after their collapse. They deliver electrical energy to the heart to restore its normal rhythm.

15 Nov 2010

Emerging blood thinners to prevent stroke

As blood thinners emerge in the market for stroke prevention many experts believe is still too early to predict how they will stack up in the $15 billion a year market.

15 Nov 2010

MEDecision earns NCQA Healthcare Effectiveness Data and Information Set Software Certification

MEDecision, Inc., a leading provider of collaborative healthcare management solutions, has earned the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS®) Software Certification for its programs that identify "care opportunities."

15 Nov 2010

BioTime third quarter total revenues increase 82% to $815,284

BioTime, Inc. today reported financial results for the quarter ended September 30, 2010 and provided an update on recent corporate developments.

15 Nov 2010

Biostar third quarter net income increases 9.8% to $3.4 million

Biostar Pharmaceuticals, Inc., Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced financial results for the third quarter ended September 30, 2010.

15 Nov 2010

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Clinical Data, Inc., today announced that results of studies using its FAMILION® genetic testing were presented at the 2010 American Heart Association (AHA) meeting. PGxHealth, a division of Clinical Data, together with its collaborators, presented results from the largest, most comprehensive studies of genetic variation associated with certain cardiac conditions that were revealed using FAMILION testing.

15 Nov 2010

Weikang third quarter revenue increases 55.2% to record $17.4 million

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced record fiscal 2010 third quarter results for period ended September 30, 2010.

15 Nov 2010